In this regard, malignancies with cancerous tumors are targeted through numerous antigens that are categorized into distinct groups based on their function, whereas hematological cancers are targeted through CD markers such as CD20, CD30, CD33, and CD52 (66). This evidence concerns the gene CD52 and hematopoietic and lymphoid cell neoplasm.